← Back to headlines
Regeneron Exceeds Q1 Estimates Driven by Dupixent Sales
Regeneron Pharmaceuticals reported first-quarter earnings that topped analyst estimates, largely attributed to the strong momentum of its drug Dupixent.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
